Savara Inc (NASDAQ:SVRA) Holdings Raised by Teachers Retirement System of The State of Kentucky

Teachers Retirement System of The State of Kentucky raised its stake in shares of Savara Inc (NASDAQ:SVRA) by 148.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 132,425 shares of the company’s stock after purchasing an additional 79,022 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Savara were worth $561,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Vestal Point Capital LP boosted its position in Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after purchasing an additional 1,600,000 shares during the last quarter. Frazier Life Sciences Management L.P. raised its stake in shares of Savara by 103.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Savara by 198.2% during the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after buying an additional 3,443,541 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Savara by 54.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 690,609 shares of the company’s stock valued at $2,928,000 after buying an additional 242,249 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Savara by 238.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock worth $3,865,000 after buying an additional 642,259 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Stock Performance

Shares of SVRA opened at $3.02 on Thursday. The company has a market capitalization of $518.29 million, a PE ratio of -7.02 and a beta of 0.92. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. Savara Inc has a one year low of $2.82 and a one year high of $5.70. The company’s fifty day moving average price is $3.49 and its 200 day moving average price is $4.00.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). As a group, analysts expect that Savara Inc will post -0.45 earnings per share for the current year.

Insider Buying and Selling at Savara

In related news, Director Joseph S. Mccracken bought 20,000 shares of Savara stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the completion of the purchase, the director now owns 210,837 shares in the company, valued at approximately $621,969.15. This represents a 10.48 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of the business’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the transaction, the chief executive officer now owns 1,536,379 shares in the company, valued at $5,085,414.49. This represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.13% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on SVRA. Evercore ISI reissued an “in-line” rating and issued a $5.00 target price (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. Finally, HC Wainwright lowered their target price on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.